In a recent showdown between the FDA and pharmaceutical giants Eli Lilly and Novo Nordisk, the regulatory agency accused the companies of understating the risks associated with their GLP-1 weight loss drugs during a prime time special with Oprah Winfrey.
The FDA’s latest crackdown on deceptive and misleading advertisements targeted Eli Lilly for its promotion of the weight loss drug Zepbound, specifically calling out an ad that aired during Oprah Winfrey’s show in March 2024. Novo Nordisk, a competitor in the GLP-1 market, also received a letter from the FDA regarding the same special.
The agency’s efforts to enforce stricter regulations on pharmaceutical advertising have been unveiled, with a focus on ensuring comprehensive risk disclosures and holding companies accountable for their marketing practices. The release of these enforcement letters to various companies in the pharmaceutical industry has been met with anticipation from industry observers.
Of particular note are the letters sent to Novo and Lilly, where the FDA scrutinized the companies for what appears to be the integration of their GLP-1 products into Oprah’s 42-minute TV special as a form of advertisement.
The FDA’s letter to Lilly’s CEO highlighted the omission of crucial safety information related to a specific genetic condition, multiple endocrine neoplasia type 2 (MEN 2), which poses risks for patients using tirzepatide, the active ingredient in Lilly’s drugs. Despite some mention of side effects during the TV special, the FDA deemed the information insufficient, especially regarding the MEN 2 risk associated with tirzepatide treatment.
The regulatory agency also pointed out other omitted risks such as severe gastrointestinal disease, acute kidney injury, hypersensitivity reactions, and diabetic retinopathy complications, all of which are outlined in the product labels. The FDA took issue with Lilly’s spokesperson allegedly downplaying the risks, particularly in relation to serious health effects, which are clearly indicated in the drug’s boxed warning.
Similarly, the FDA’s letter to Novo raised concerns about the omission of the MEN 2 risk and highlighted a segment in which a patient described stopping GLP-1 treatment due to severe side effects. Novo’s spokesperson was criticized for describing the side effects as “overhyped” and “mild to moderate,” which the FDA viewed as downplaying the severity of the risks associated with the medications.
Both Lilly and Novo were instructed to cease any misleading promotions outlined in the letters and respond within 15 days with a plan to disseminate accurate and complete corrective communications to address the concerns raised by the FDA.
In addition to Novo and Lilly, other pharmaceutical companies such as AstraZeneca, Bristol Myers Squibb, BridgeBio Pharma, and Alnylam Pharma were also recipients of enforcement letters for various advertisements.
Key Takeaways:
1. The FDA is cracking down on deceptive pharmaceutical advertising, focusing on comprehensive risk disclosures.
2. Eli Lilly and Novo Nordisk received letters for understating the risks of their GLP-1 weight loss drugs during a TV special with Oprah Winfrey.
3. Companies must respond promptly and take corrective action to address the FDA’s concerns about misleading promotions.
Additional Thoughts:
“The FDA’s vigilance in ensuring transparency and accuracy in pharmaceutical advertising sets a crucial precedent for the industry’s commitment to prioritizing consumer safety and informed decision-making. This enforcement serves as a reminder that responsible marketing practices are essential in promoting public health and trust in the healthcare system.”
Tags: downstream
Read more on biospace.com